Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open-Label, Single-Arm Study of The Efficacy, Safety, and Pharmacokinetic Behavior of Leuprolide Mesylate Injectable Suspension (LMIS 25 mg) in Subjects With Prostate Cancer

NCT03261999 is registered in ClinicalTrials.gov with Foresee Pharmaceuticals Co., Ltd. as lead sponsor.

NCT NCT03261999
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03261999 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open-Label, Single-Arm Study of The Efficacy, Safety, and Pharmacokinetic Behavior of Leuprolide Mesylate Injectable Suspension (LMIS 25 mg) in Subjects With Prostate Cancer
Lead sponsor
Foresee Pharmaceuticals Co., Ltd.
Phase
Phase 3
Overall status
Completed
Start date
September 26, 2017
Completion date
February 1, 2019
Enrollment
144 (actual)
Sites
21

Conditions

As the registry lists them; a condition with its own page is linked.

prostatic neoplasms